The present application provides microbiota-related compositions, methods, and dosing regimens for treating various microbiota-related disorders with improved cure rates by replacing or supplementing or modifying a subject's colon microbiota.

The invention relates to the isolation or extraction of exosomes.

A method of manufacturing prebiotic dietary fibers and probiotic encapsulated or associated material capable of affording thermal or mechanical stresses resulting from industrial feed processing as well as compositions including prebiotic dietary fibers and probiotic-fiber complexes.

A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.

A method of determining tolerance to an agent in a healthy subject is disclosed. The method comprises: (a) determining a signature of a microbiome in a sample of the healthy subject who has been subjected to the agent or condition; and (b) comparing the signature of the microbiome of the healthy subject to at least one reference signature of a pathological microbiome, wherein when the signature of the microbiome of the healthy subject is statistically significantly similar to the reference signature of the pathological microbiome, it is indicative that the healthy subject is intolerant to the agent.

Disclosed is a novel recombinant protein UK 114 in stable polymer form for use in the treatment, diagnosis and prevention of malignant solid and systemic tumours.

A method for producing a capsule, including cooling a suspension so as to gel a thermoresponsive polymer including a core 8 formed from a gel of an ionically-bonded polymer and form a shell (17) of a hydrogel, the suspension being obtained by suspending, in oil (10), a sol (9) of the thermoresponsive polymer, and then using a chelating agent to solate the core so as to hollow out the inside.

A method for producing a capsule, including cooling a suspension so as to gel a thermoresponsive polymer including a core 8 formed from a gel of an ionically-bonded polymer and form a shell (17) of a hydrogel, the suspension being obtained by suspending, in oil (10), a sol (9) of the thermoresponsive polymer, and then using a chelating agent to solate the core so as to hollow out the inside.

The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of Clostridia sp. or coccidia sp based diseases or other enteric diseases or by generally improving gastro intestinal health or function.

The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of Clostridia sp. or coccidia sp based diseases or other enteric diseases or by generally improving gastro intestinal health or function.